IMCR Latest Press Releases

-- October 29, 2026 --

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting Globe Newswire 9:00 AM

-- October 15, 2026 --

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI - its first tissue-specific autoimmune candidate - for patients with type 1 diabetes Globe Newswire 7:00 AM

-- September 14, 2026 --

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK (tebentafusp) in previously treated advanced melanoma Globe Newswire 7:00 AM

-- September 1, 2026 --

Immunocore to present at upcoming investor conferences Globe Newswire 7:00 AM

-- August 6, 2026 --

Immunocore reports second quarter financial results and provides a business update Globe Newswire 7:00 AM

-- July 30, 2026 --

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 Globe Newswire 7:00 AM

-- May 31, 2026 --

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes